Log on / register
Feedback | Support | My details
Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.
Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ
Malar J 2008, 7:127
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Review    
Safety profile of Coartem®: the evidence base
Falade C, Manyando C
Malaria Journal 2009, 8(Suppl 1):S6 (12 October 2009)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

2.


Review    
The clinical efficacy of artemether/lumefantrine (Coartem®)
Makanga M, Krudsood S
Malaria Journal 2009, 8(Suppl 1):S5 (12 October 2009)
[Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

3.


Research    
Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG
Malaria Journal 2009, 8:204 (26 August 2009)
[Abstract] [Full Text] [PDF] [PubMed] [Related articles]

4.


Research    
A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children
Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, Nielsen MV, Vohwinkel J, Hogan B, Kreuels B, Bührlen M, Loag W, Ansong D, May J
Malaria Journal 2008, 7:261 (19 December 2008)
[Abstract] [Full Text] [PDF] [PubMed] [Related articles]


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]

© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.